Monitor adoption metrics and any revenue contribution from LEAF in upcoming quarterly reports. The launch is a positive signal for Smith+Nephew's wound management innovation pipeline but is unlikely to materially move the stock given the company's large revenue base. Watch for competitor responses in the pressure injury prevention space.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 1 $29.48entry
- T+1 · 6mo ago −0.41%α −0.55% · $29.36
- T+5 · 5mo ago +3.83%α +6.58% · $30.61
- T+20 · 5mo ago −2.27%α −0.97% · $28.81
- T+60 · 3mo ago −0.88%α −2.11% · $29.22
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Smith+Nephew announced the US launch of the next-generation LEAF Patient Monitoring System, a cloud-based platform using wearable sensors to reduce hospital-acquired pressure injuries (HAPIs). The system claims up to 73% reduction in HAPI odds and up to $1.8 million in estimated savings per critical care facility, addressing a $26.8B annual US burden. This product launch is a positive incremental catalyst for Smith+Nephew's Advanced Wound Management segment but does not materially change the company's overall $6.2B revenue base.
Key Financial Metrics
Key Facts
- LEAF Next Generation is now commercially available in the US.
- System uses a wearable sensor to monitor patient mobility and provide real-time turn status updates.
- Claims to reduce odds of HAPIs by up to 73% vs standard of care.
- Delivers up to $1.8 million in estimated savings in one critical care facility.
- HAPIs place a $26.8B annual burden on the US economy.
- Smith+Nephew generated annual sales of $6.2 billion in 2025.
- Product is cloud-hosted and integrates with hospital EMRs.
Financial Impact
Up to $1.8 million in estimated savings per critical care facility; $26.8B annual US HAPI burden addressed; product launch is incremental to $6.2B total revenue.
Risk Factors
- Adoption may be slower than expected due to hospital budget constraints or workflow integration challenges.
- Competing technologies could limit market share gains.
- No financial guidance or revenue targets were provided for the product.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304677 |
Track record
42 reports on SNN
5 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +8.02% at T+20 after the Jun 30, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 1/10 Entry $31.00 Now $30.97 −0.10% settles Nov 19
- Nov 4, 202612d ago 6-K Bearish 6/10 No price data
- Nov 4, 202612d ago 6-K Bearish 6/10 Entry $32.46 to $31.04 Now $30.97 +4.59% ▲ +4.37% +3.46% vs SPY
- Nov 2, 202614d ago 6-K Neutral 4/10 Entry $30.24 to $31.05 Now $30.97 +2.41% ▲ +2.68% +2.60% vs SPY
- Oct 22, 202625d ago 6-K Neutral 2/10 Entry $30.88 to $30.22 Now $30.97 +0.29% ▼ −2.14% −2.84% vs SPY
- Oct 8, 20265w ago 6-K Neutral 2/10 Entry $26.96 to $29.09 Now $30.97 +14.87% ▲ +7.90% +8.18% vs SPY
- Oct 1, 20266w ago 6-K Neutral 2/10 Entry $26.58 to $26.96 Now $30.97 +16.52% ▲ +1.43% +0.13% vs SPY
- Oct 1, 20266w ago 6-K Neutral 2/10 Entry $26.58 to $26.96 Now $30.97 +16.52% ▲ +1.43% +0.13% vs SPY
- Sep 23, 20267w ago Press Release Neutral 3/10 Entry $26.82 to $26.96 Now $30.97 +15.47% ▲ +0.52% +1.20% vs SPY
- Sep 23, 20267w ago Press Release Neutral 3/10 Entry $26.82 to $26.96 Now $30.97 +15.47% ▲ +0.52% +1.20% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers